PML AS A POTENTIAL PREDICTIVE FACTOR OF EFFICACY OF OXALIPLATIN BASED FIRST LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS

被引：0
|
作者：
Vincenzi, B. [1 ]
Perrone, G. [1 ]
Santini, D. [1 ]
Loupakis, F. [2 ]
Graziano, F. [3 ]
Ruzzo, A. [4 ]
Venditti, O. [1 ]
OnettiMuda, A. [1 ]
Falcone, A. [2 ]
Tonini, G. [1 ]
机构：
[1] Univ Campus Biomed Rome, Rome, Italy
[2] Ist Toscano Tumori, Dept Oncol, Livomo, Italy
[3] Hosp Pesaro, Med Oncol Unit, Pesaro, Italy
[4] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [31] A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer
    Gelibter, Alain J.
    Gamucci, Teresa
    Pollera, Camillo F.
    Di Costanzo, Francesco
    Nuzzo, Carmen
    Gabriele, Angela
    Signorelli, Carlo
    Gasperoni, Silvia
    Ferraresi, Virginia
    Giannarelli, Diana
    Cognetti, Francesco
    Zeuli, Massimo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) : 2117 - 2123
  • [32] Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer
    Grande, C., Sr.
    Quintero, G.
    Mel, J. R.
    Huidobro, G.
    Campos, B.
    Candamio, S.
    Mendez, J. C.
    Salgado, M.
    Alvarez, E.
    Casal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy
    Mangia, Anita
    Caldarola, Lucia
    Dell'Endice, Stefania
    Scarpi, Emanuela
    Saragoni, Luca
    Monti, Manlio
    Santini, Daniele
    Brunetti, Oronzo
    Simone, Giovanni
    Silvestris, Nicola
    CANCER BIOLOGY & THERAPY, 2015, 16 (08) : 1140 - 1147
  • [34] The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy
    Mangia, A.
    Simone, G.
    Dell'Endice, S.
    Scarpi, E.
    Saragoni, L.
    Monti, M.
    Santini, D.
    Brunetti, O.
    Silvestris, N.
    ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [35] Efficacy and safety of bevacizumab with standard first-line fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer: First beat
    Rivera, F.
    Cunningham, D.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    Dibartolomeo, M.
    Mazier, M.
    Andre, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [36] Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
    Chibaudel, Benoist
    Bonnetain, Franck
    Tournigand, Christophe
    Bengrine-Lefevre, Leila
    Teixeira, Luis
    Artru, Pascal
    Desrame, Jerome
    Larsen, Annette K.
    Andre, Thierry
    Louvet, Christophe
    de Gramont, Aimery
    ONCOLOGIST, 2011, 16 (09): : 1228 - 1238
  • [37] The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer
    Hayashi, Naomi
    Kanda, Mitsuro
    Omae, Kenji
    Kodera, Yasuhiro
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2020, 82 (04): : 603 - 611
  • [38] The XPD lys751gln polymorphism in colorectal cancer patients treated in first line chemotherapy with 5-FU-oxaliplatin or 5-FU-irinotecan combinations:: a prognostic factor or a predictive marker of oxaliplatin efficiency?
    Le Morvan, V.
    Smith, D.
    Bellott, R.
    Brouste, V.
    Soubeyran, I.
    Rullier, A.
    Belleannee, G.
    Robert, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 48 - 48
  • [39] Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
    Abraham, Jim P.
    Magee, Daniel
    Cremolini, Chiara
    Antoniotti, Carlotta
    Halbert, David D.
    Xiu, Joanne
    Stafford, Phillip
    Berry, Donald A.
    Oberley, Matthew J.
    Shields, Anthony F.
    Marshall, John L.
    Salem, Mohamed E.
    Falcone, Alfredo
    Grothey, Axel
    Hall, Michael J.
    Venook, Alan P.
    Lenz, Heinz-Josef
    Helmstetter, Anthony
    Korn, W. Michael
    Spetzler, David B.
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1174 - 1183
  • [40] CONTINUATION OF OXALIPLATIN IS A POTENTIAL PREDICTIVE FACTOR IN ADJUVANT FOLFOX FOR STAGE IIIB OR IV COLORECTAL CANCER
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keisho
    Kuboki, Yasutoshi
    Watanabe, Toshiyasu
    Fujimoto, Yoshiya
    Ueno, Masashi
    Kuroyanagi, Hiroya
    Oya, Masatoshi
    Yamamoto, Noriko
    Hatake, Kiyohiko
    ANNALS OF ONCOLOGY, 2010, 21 : 30 - 30
12345